PDIA3P1: A Potential Drug Target and Biomarker (G171423)

Target Name: PDIA3P1

NCBI ID: G171423

PDIA3P1

Other Name(s): ERp60 | protein disulfide isomerase family A member 3 pseudogene 1 | PDIA3P | GRP58P | Protein disulfide isomerase family A member 3 pseudogene 1

PDIA3P1: A Potential Drug Target and Biomarker

PDIA3P1, also known as PD-L1, is a protein that is expressed in various tissues throughout the body, including the skin, lung, liver, and pancreas. It is a key regulator of immune responses and has been implicated in the development and progression of several diseases, including cancer.

PDIA3P1 functions as a negative regulator of the T-cell receptor, which is responsible for cell survival and proliferation. When the T-cell receptor is activated, PDIA3P1 is recruited to the receptor and works to inhibit its activity, thereby promoting the death of infected or damaged cells.

PDIA3P1 is also involved in the regulation of inflammation and has been shown to play a role in the development of autoimmune diseases. In addition, PDIA3P1 has been linked to the development of certain types of cancer, including melanoma and pancreatic cancer.

Due to its involvement in these processes, PDIA3P1 has emerged as a promising drug target and biomarker for a variety of diseases. Researchers are currently working to develop drugs that can specifically target PDIA3P1 and modulate its activity to treat various diseases.

One approach to targeting PDIA3P1 is to use small molecules, such as drugs that can inhibit the activity of PDIA3P1. These molecules have been shown to be effective in preclinical studies and are now being tested in clinical trials.

Another approach to targeting PDIA3P1 is to use antibodies that are designed to specifically recognize and target PDIA3P1. These antibodies have been shown to be effective in preclinical studies and are now being tested in clinical trials.

In addition to its potential as a drug target, PDIA3P1 is also being investigated as a biomarker for several diseases. For example, researchers have shown that PDIA3P1 is downregulated in the skin and lymphoid organs of individuals with melanoma, indicating that it may be a useful biomarker for this disease. Similarly, PDIA3P1 has been shown to be downregulated in the tissues of individuals with pancreatic cancer, suggesting that it may be a useful biomarker for this disease as well.

Overall, PDIA3P1 is a protein that has the potential to be a drug target and biomarker for a variety of diseases. Further research is needed to fully understand its role in these processes and to develop effective treatments.

Protein Name: Protein Disulfide Isomerase Family A Member 3 Pseudogene 1

The "PDIA3P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDIA3P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets